Discussion
unresectable HCC, tumor, cancer vaccine, HCC
TUMOR
Current clinical trials have shown that less than one patient out of three achieved clinical responses to anti–PD-L1 and anti-angiogenic in first-line treatment for patients with unresectable HCC. Combining atezolizumab plus bevacizumab with a CD4 Th1-inducer cancer vaccine derived from telomerase, in order to activate antitumor T cell immunity and bypass the immunosuppression in the tumor microenvironment in HCC, might increase the number of patients achieving a clinical benefit and the immunological efficacy.